Description

Halozyme Therapeutics: ENHANZE, Hypercon, and the Blueprint for Durable Biotech Cash Flows!

Halozyme Therapeutics delivered a significant year of growth in 2025, highlighted by expanding its drug delivery portfolio and achieving remarkable financial performance. The company achieved a 38% increase in total revenue, reaching a record $1.4 billion, mainly driven by a substantial 52% growth in royalty revenue, totaling $868 million. This robust performance was fueled by the continued adoption of ENHANZE-enabled products, such as DARZALEX SC, PHESGO, and VYVGART Hytrulo. Positively, Halozyme expanded its portfolio by acquiring Elektrofi’s Hypercon technology and Surf Bio’s hyperconcentration technology, enhancing its capabilities in subcutaneous drug delivery. These acquisitions are expected to broaden the company’s collaboration opportunities across various therapeutic areas. Furthermore, the company achieved significant regulatory approvals through partners such as Johnson & Johnson and Roche, contributing to blockbuster potential for drugs like DARZALEX, PHESGO, and VYVGART.